A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients

Pierre Sabouret, Denis Angoulvant, Atul Pathak, Francesco Costa, Théo Pezel, Erin D. Michos

Research output: Contribution to journalReview article

Abstract

Purpose of Review: There has been significant progress made during the last few decades in the management of atherosclerotic cardiovascular disease (ASCVD). Despite this, residual risk remains an unmet need for secondary prevention and high-risk primary prevention patients. First onset and recurrent cardiovascular events remain a major issue despite recommendations for a healthy lifestyle and current optimal medical therapy, which includes the use of maximally tolerated statin therapy plus or minus add-on ezetimibe therapy. Recent Findings: These findings have led to the development of new treatments that modulate lipid targets in order to improve prognosis of these patients at highest ASCVD risk. These include inhibitors of proprotein convertase subtilisin/kexin type 9 (evolocumab and alirocumab), an inhibitor of adenosine triphosphate citrate lyase (bempedoic acid), and a high-dose omega-3 formulation (icosapent ethyl), which have been evaluated in large phase III randomized clinical trials and/or currently undergoing continued study. The clinical efficacy of these drugs and their application in cardiovascular prevention are discussed in this review article. Of note, there are other novel lipid-lowering therapeutics with potential cardiovascular benefit, not discussed in this review, that include inhibitors of lipoprotein (a), apolipoprotein CIII, and angiopoietin-like 3. These drugs may also play a future role in reducing residual lipid-mediated ASCVD risk, if efficacy and safety confirmed in cardiovascular outcome trials. Summary: In this review, we provide an overview of the current knowledge regarding treatment with several new lipid strategies for high-risk patients, along with suggestions on their use in ASCVD prevention management.

Original languageEnglish (US)
Article number32
JournalCurrent Cardiovascular Risk Reports
Volume13
Issue number11
DOIs
StatePublished - Nov 1 2019
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiovascular Diseases
Lipids
citrate (pro-3S)-lyase
Therapeutics
Angiopoietins
Apolipoprotein C-III
Phase III Clinical Trials
Lipoprotein(a)
Primary Prevention
Disease Management
Secondary Prevention
Pharmaceutical Preparations
Ezetimibe
Randomized Controlled Trials
Adenosine Triphosphate
Safety
Acids

Keywords

  • Bempedoic acid
  • Eicosapentaenoic acid
  • Inclisiran
  • Lipid-lowering treatments
  • PCSK9 inhibitors
  • Residual risk

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A Look Beyond Statins and Ezetimibe : a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients. / Sabouret, Pierre; Angoulvant, Denis; Pathak, Atul; Costa, Francesco; Pezel, Théo; Michos, Erin D.

In: Current Cardiovascular Risk Reports, Vol. 13, No. 11, 32, 01.11.2019.

Research output: Contribution to journalReview article

@article{6a6652c25c684c559bb60520cb70cf3d,
title = "A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients",
abstract = "Purpose of Review: There has been significant progress made during the last few decades in the management of atherosclerotic cardiovascular disease (ASCVD). Despite this, residual risk remains an unmet need for secondary prevention and high-risk primary prevention patients. First onset and recurrent cardiovascular events remain a major issue despite recommendations for a healthy lifestyle and current optimal medical therapy, which includes the use of maximally tolerated statin therapy plus or minus add-on ezetimibe therapy. Recent Findings: These findings have led to the development of new treatments that modulate lipid targets in order to improve prognosis of these patients at highest ASCVD risk. These include inhibitors of proprotein convertase subtilisin/kexin type 9 (evolocumab and alirocumab), an inhibitor of adenosine triphosphate citrate lyase (bempedoic acid), and a high-dose omega-3 formulation (icosapent ethyl), which have been evaluated in large phase III randomized clinical trials and/or currently undergoing continued study. The clinical efficacy of these drugs and their application in cardiovascular prevention are discussed in this review article. Of note, there are other novel lipid-lowering therapeutics with potential cardiovascular benefit, not discussed in this review, that include inhibitors of lipoprotein (a), apolipoprotein CIII, and angiopoietin-like 3. These drugs may also play a future role in reducing residual lipid-mediated ASCVD risk, if efficacy and safety confirmed in cardiovascular outcome trials. Summary: In this review, we provide an overview of the current knowledge regarding treatment with several new lipid strategies for high-risk patients, along with suggestions on their use in ASCVD prevention management.",
keywords = "Bempedoic acid, Eicosapentaenoic acid, Inclisiran, Lipid-lowering treatments, PCSK9 inhibitors, Residual risk",
author = "Pierre Sabouret and Denis Angoulvant and Atul Pathak and Francesco Costa and Th{\'e}o Pezel and Michos, {Erin D.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1007/s12170-019-0627-8",
language = "English (US)",
volume = "13",
journal = "Current Cardiovascular Risk Reports",
issn = "1932-9520",
publisher = "Current Medicine Group",
number = "11",

}

TY - JOUR

T1 - A Look Beyond Statins and Ezetimibe

T2 - a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients

AU - Sabouret, Pierre

AU - Angoulvant, Denis

AU - Pathak, Atul

AU - Costa, Francesco

AU - Pezel, Théo

AU - Michos, Erin D.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Purpose of Review: There has been significant progress made during the last few decades in the management of atherosclerotic cardiovascular disease (ASCVD). Despite this, residual risk remains an unmet need for secondary prevention and high-risk primary prevention patients. First onset and recurrent cardiovascular events remain a major issue despite recommendations for a healthy lifestyle and current optimal medical therapy, which includes the use of maximally tolerated statin therapy plus or minus add-on ezetimibe therapy. Recent Findings: These findings have led to the development of new treatments that modulate lipid targets in order to improve prognosis of these patients at highest ASCVD risk. These include inhibitors of proprotein convertase subtilisin/kexin type 9 (evolocumab and alirocumab), an inhibitor of adenosine triphosphate citrate lyase (bempedoic acid), and a high-dose omega-3 formulation (icosapent ethyl), which have been evaluated in large phase III randomized clinical trials and/or currently undergoing continued study. The clinical efficacy of these drugs and their application in cardiovascular prevention are discussed in this review article. Of note, there are other novel lipid-lowering therapeutics with potential cardiovascular benefit, not discussed in this review, that include inhibitors of lipoprotein (a), apolipoprotein CIII, and angiopoietin-like 3. These drugs may also play a future role in reducing residual lipid-mediated ASCVD risk, if efficacy and safety confirmed in cardiovascular outcome trials. Summary: In this review, we provide an overview of the current knowledge regarding treatment with several new lipid strategies for high-risk patients, along with suggestions on their use in ASCVD prevention management.

AB - Purpose of Review: There has been significant progress made during the last few decades in the management of atherosclerotic cardiovascular disease (ASCVD). Despite this, residual risk remains an unmet need for secondary prevention and high-risk primary prevention patients. First onset and recurrent cardiovascular events remain a major issue despite recommendations for a healthy lifestyle and current optimal medical therapy, which includes the use of maximally tolerated statin therapy plus or minus add-on ezetimibe therapy. Recent Findings: These findings have led to the development of new treatments that modulate lipid targets in order to improve prognosis of these patients at highest ASCVD risk. These include inhibitors of proprotein convertase subtilisin/kexin type 9 (evolocumab and alirocumab), an inhibitor of adenosine triphosphate citrate lyase (bempedoic acid), and a high-dose omega-3 formulation (icosapent ethyl), which have been evaluated in large phase III randomized clinical trials and/or currently undergoing continued study. The clinical efficacy of these drugs and their application in cardiovascular prevention are discussed in this review article. Of note, there are other novel lipid-lowering therapeutics with potential cardiovascular benefit, not discussed in this review, that include inhibitors of lipoprotein (a), apolipoprotein CIII, and angiopoietin-like 3. These drugs may also play a future role in reducing residual lipid-mediated ASCVD risk, if efficacy and safety confirmed in cardiovascular outcome trials. Summary: In this review, we provide an overview of the current knowledge regarding treatment with several new lipid strategies for high-risk patients, along with suggestions on their use in ASCVD prevention management.

KW - Bempedoic acid

KW - Eicosapentaenoic acid

KW - Inclisiran

KW - Lipid-lowering treatments

KW - PCSK9 inhibitors

KW - Residual risk

UR - http://www.scopus.com/inward/record.url?scp=85073506314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073506314&partnerID=8YFLogxK

U2 - 10.1007/s12170-019-0627-8

DO - 10.1007/s12170-019-0627-8

M3 - Review article

AN - SCOPUS:85073506314

VL - 13

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 11

M1 - 32

ER -